Chemistry:NYX-2925

From HandWiki

NYX-2925 is a compound derived from rapastinel which acts as a positive allosteric modulator of the NMDA receptor. It has been researched as a potential antidepressant and treatment for neuropathic pain.[1][2][3][4][5]

References

  1. ↑ "NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory". The International Journal of Neuropsychopharmacology 21 (3): 242–254. March 2018. doi:10.1093/ijnp/pyx096. PMID 29099938. 
  2. ↑ "NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain". The Journal of Pharmacology and Experimental Therapeutics 366 (3): 485–497. September 2018. doi:10.1124/jpet.118.249409. PMID 29986951. 
  3. ↑ "The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC". Neurobiology of Pain 7. 2020. doi:10.1016/j.ynpai.2019.100039. PMID 31909296. 
  4. ↑ "NYX-2925 induces metabotropic N-methyl-d-aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor". Journal of Neurochemistry 152 (5): 523–541. March 2020. doi:10.1111/jnc.14845. PMID 31376158. 
  5. ↑ "New advances in small molecule drugs targeting NMDA receptors". Acta Pharmacologica Sinica 47 (1): 3–21. January 2026. doi:10.1038/s41401-025-01675-8. PMID 41188625. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:NYX-2925&oldid=4308890"